Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Qiagen ( (QGEN) ) is now available.
QIAGEN has reported a management-related share consolidation involving board member Elizabeth Tallett following the company’s previously announced synthetic share repurchase program. Under the terms of this capital measure, every 20 issued QIAGEN shares were consolidated into 19, resulting in Tallett’s holdings being reduced by 2,587 shares to a total of 49,124 common shares, a technical adjustment that reflects the broader capital structure optimization approved by shareholders and implemented outside a trading venue.
The most recent analyst rating on (QGEN) stock is a Hold with a $48.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V., based in Venlo, Netherlands, is a life sciences and molecular diagnostics company whose shares are listed on multiple European exchanges as well as the NYSE and Swiss markets. The company’s primary securities include common shares under ISIN NL0015002SN0, reflecting a broad international investor base.
Average Trading Volume: 1,155,025
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.99B
Learn more about QGEN stock on TipRanks’ Stock Analysis page.